1. Home
  2. CVAC vs DXPE Comparison

CVAC vs DXPE Comparison

Compare CVAC & DXPE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CVAC
  • DXPE
  • Stock Information
  • Founded
  • CVAC 2000
  • DXPE 1908
  • Country
  • CVAC Germany
  • DXPE United States
  • Employees
  • CVAC N/A
  • DXPE N/A
  • Industry
  • CVAC Biotechnology: Pharmaceutical Preparations
  • DXPE Industrial Machinery/Components
  • Sector
  • CVAC Health Care
  • DXPE Industrials
  • Exchange
  • CVAC Nasdaq
  • DXPE Nasdaq
  • Market Cap
  • CVAC 812.1M
  • DXPE 795.0M
  • IPO Year
  • CVAC 2020
  • DXPE 1996
  • Fundamental
  • Price
  • CVAC $4.10
  • DXPE $102.67
  • Analyst Decision
  • CVAC Hold
  • DXPE Buy
  • Analyst Count
  • CVAC 3
  • DXPE 1
  • Target Price
  • CVAC $10.00
  • DXPE $75.00
  • AVG Volume (30 Days)
  • CVAC 1.2M
  • DXPE 366.1K
  • Earning Date
  • CVAC 11-12-2024
  • DXPE 03-06-2025
  • Dividend Yield
  • CVAC N/A
  • DXPE N/A
  • EPS Growth
  • CVAC N/A
  • DXPE 17.97
  • EPS
  • CVAC N/A
  • DXPE 3.87
  • Revenue
  • CVAC $70,565,734.00
  • DXPE $1,738,170,000.00
  • Revenue This Year
  • CVAC $742.57
  • DXPE $8.07
  • Revenue Next Year
  • CVAC N/A
  • DXPE $4.19
  • P/E Ratio
  • CVAC N/A
  • DXPE $26.51
  • Revenue Growth
  • CVAC 75.11
  • DXPE 3.60
  • 52 Week Low
  • CVAC $2.22
  • DXPE $31.10
  • 52 Week High
  • CVAC $5.28
  • DXPE $103.61
  • Technical
  • Relative Strength Index (RSI)
  • CVAC 62.06
  • DXPE 84.20
  • Support Level
  • CVAC $3.89
  • DXPE $96.58
  • Resistance Level
  • CVAC $4.32
  • DXPE $102.18
  • Average True Range (ATR)
  • CVAC 0.33
  • DXPE 3.65
  • MACD
  • CVAC 0.03
  • DXPE 1.50
  • Stochastic Oscillator
  • CVAC 54.27
  • DXPE 96.03

About CVAC CureVac N.V.

CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid, or mRNA. The company was founded in 2000 and had its initial public offering in August 2020. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and Covid vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.

About DXPE DXP Enterprises Inc.

DXP Enterprises Inc is a distributor of products and services to industrial customers in the United States, Canada, Mexico, and Dubai. The company's reportable segments include Service Centers, Innovative Pumping Solutions and Supply Chain Services. It generates maximum revenue from the Service Centers segment. The company offers pumping solutions, supply chain services and maintenance, repair, operating and production services for rotating equipment, bearings and power transmissions, industrial supplies and safety products. DXP Enterprises serves the General Industrial, Oil & Gas, Food & Beverage, Water & Wastewater, Chemical, Transportation, Aerospace & Other.

Share on Social Networks: